AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Previously Treated Non Small Cell Lung Cancer
Conditions
Previously Treated Non Small Cell Lung Cancer
Trial Timeline
Mar 1, 2014 → May 1, 2015
NCT ID
NCT02087176About AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim
AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim is a phase 2 stage product being developed by AstraZeneca for Previously Treated Non Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02087176. Target conditions include Previously Treated Non Small Cell Lung Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Previously Treated Non Small Cell Lung Cancer were approved
Approved (1) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02087176 | Phase 2 | Terminated |
Competing Products
8 competing products in Previously Treated Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 | Jiangsu Hengrui Medicine | Phase 3 | 44 |
| AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin | AstraZeneca | Phase 2 | 27 |
| UFOX + Cetuximab + FOLFOX4 + Cetuximab | Merck | Phase 2 | 35 |
| Idelalisib + Nab-paclitaxel + mFOLFOX6 | Gilead Sciences | Phase 1 | 21 |
| Bosutinib | Pfizer | Approved | 35 |
| CRS-207 + CRS-207 + nivolumab + GVAX + CY | Bristol Myers Squibb | Phase 2 | 35 |
| Lenalidomide + Dexamethasone + Elotuzumab | Bristol Myers Squibb | Phase 3 | 32 |
| Oxaliplatin | Sanofi | Phase 2 | 31 |